This review will summarize recent advancements in the study of inhibiting the NOTCH1, PI3K–AKT, and Cyclin D3:CDK4/6 pathways as therapeutic strategies for T-ALL. The gene discussed is AKT1; the disease is acute lymphoblastic leukemia.